Dual antiplatelet therapy duration after percutaneous coronary intervention in high bleeding risk: a meta-analysis of randomized trials

Costa, Francesco; Montalto, Claudio; Branca, Mattia; Hong, Sung-Jin; Watanabe, Hirotoshi; Franzone, Anna; Vranckx, Pascal; Hahn, Joo-Yong; Gwon, Hyeon-Cheol; Feres, Fausto; Jang, Yangsoo; De Luca, Giuseppe; Kedhi, Elvin; Cao, Davide; Gabriel Steg, Philippe; L Bhatt, Deepak; W Stone, Gregg; Micari, Antonio; Windecker, Stephan; Kimura, Takeshi; Hong, Myeong-Ki; Mehran, Roxana; Valgimigli, Marco

doi:10.1093/eurheartj/ehac706

Public

Dual antiplatelet therapy duration after percutaneous coronary intervention in high bleeding risk: a meta-analysis of randomized trials

Shared by NobleBlocks on Dec 7, 2022 • 12:00 AM UTC

Authors:

Francesco Costa

Claudio Montalto

Mattia Branca

Abstract

Abstract Aims The optimal duration of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) in patients at high bleeding risk (HBR) is still debated. The current study, using the totality of existing evidence, evaluated the impact of an abbreviated DAPT regimen in HBR patie...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!